Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Short-term Investments: 2010-2025

Historic Short-term Investments for Ligand Pharmaceuticals (LGND) over the last 13 years, with Sep 2025 value amounting to $525.1 million.

  • Ligand Pharmaceuticals' Short-term Investments rose 236.58% to $525.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $525.1 million, marking a year-over-year increase of 236.58%. This contributed to the annual value of $183.9 million for FY2024, which is 24.77% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Short-term Investments stood at $525.1 million, which was up 196.11% from $177.4 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Short-term Investments peaked at $525.1 million during Q3 2025, and registered a low of $117.3 million during Q3 2022.
  • For the 3-year period, Ligand Pharmaceuticals' Short-term Investments averaged around $216.0 million, with its median value being $183.9 million (2024).
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Short-term Investments plummeted by 60.87% in 2022, and later skyrocketed by 236.58% in 2025.
  • Ligand Pharmaceuticals' Short-term Investments (Quarterly) stood at $321.6 million in 2021, then plummeted by 48.11% to $166.9 million in 2022, then decreased by 11.69% to $147.4 million in 2023, then rose by 24.77% to $183.9 million in 2024, then soared by 236.58% to $525.1 million in 2025.
  • Its last three reported values are $525.1 million in Q3 2025, $177.4 million for Q2 2025, and $160.9 million during Q1 2025.